On behalf of all principal COMPARE II investigators: Randomized comparison of Biolimus-eluting (Nobori) and Everolimus-eluting (Xience/Promus) stents in patients with multivessel coronary artery disease: 12-month follow -up data from COMPARE II study Pieter Cornelis Smits On behalf of all principal COMPARE II investigators: A. J. van Boven, Mariano Valdes, Antonio Serra, Jean-Jacques Goy, V. Voudris, Ramiro Trillo, J. M. Vazquez, Peter den Heijer, Ton Slagboom, A.G. Vuillomenet 1

Potential conflicts of interest Speaker’s name: Pieter C. Smits  I have the following potential conflicts of interest to report:  Research contracts: Boston Scientific, Abbott Vascular, Terumo  Consulting: Blue Medical  Employment in industry; none  Stockholder of a healthcare company; none  Owner of a healthcare company; none  Other(s): travel and speaking fees from Abbott Vascular 2

BACKGROUND COMPARE II trial Multivessel treatment The role of percutaneous coronary intervention (PCI) in the treatment of multivessel coronary artery disease (CAD) is still controversial and widely discussed. More liberal use of drug-eluting stents (DES) increased proportion of those patients undergoing PCI procedure, raising a need for more clinical evidence. The recent reported COMPARE II trial showed similar results of Biolimus-eluting Nobori stent (BES) and Everolimus-eluting Xience/Promus stent (EES) at 1-year in an all comers population. We aim to compare safety and efficacy outcomes in patients with multivessel CAD (a pre-specified study subset) treated with BES and EES in COMPARE II trial.

Methodology COMPARE II trial Multivessel treatment 12 sites Total Population: 2.700 patients Randomization 1：2 Non Inferiority Design DAPT up to 12 months 12 sites PI: Dr. P. Smits EES n = 912 BES n = 1795 Patients with Multiple vessels treated (> 1 major coronary artery and/or LM treatment) EES (Multivessel) n =230 BES (Multivessel) n = 453 Clinical Follow-up 0d 30d 12mo 3yr 5yr Primary endpoint at 12 months　: Composite of cardiac death, non-fatal myocardial Infarction and clinically indicated target vessel revascularization

Baseline Characteristics COMPARE II trial Multivessel treatment Baseline Characteristics EES 230 pts BES 453 pts P-value Age 64 0.4 Female, % 21.3 21.9 0.9 Previous cardiac history (%) Previous AMI, % 17.4 22.0 0.2 Previous PTCA, % 14.4 15.7 0.7 Previous CABG, % 5.7 5.3 0.8 CV Risk Factors (%) DM 25.7 23.0 Hypertension 61.7 57.0 0.3 Current smoker 24.4 26.5 0.6

Clinical Presentation COMPARE II trial Multivessel treatment Clinical Presentation EES BES

Lesion Characteristics COMPARE II trial Multivessel treatment Lesion Characteristics (%) EES (606 lesions) BES (1124 lesions) p Ostial 14.0 15.2 0.5 Thrombotic 12.4 11.7 0.7 Bifurcation 6.3 6.4 1.0 Calcification (moderate/severe) 33.5 35.3 Chronic Total Occluded 2.5 3.1

Lesion Location COMPARE II trial Multivessel treatment EES (606 lesions) BES (1124 lesions) p LAD 35.3 36.4 0.3 RCA 31.0 33.4 Cx 31.5 27.4 LM 2.0 2.1 SVG 0.2 0.7 8

Procedural Characteristics COMPARE II trial Multivessel treatment Procedural Characteristics EES (606 lesions) BES (1124 lesions) p Lesions treated per patient 2.57±0.90 2.48±0.77 0.2 Stent per lesion 1.43±0.75 1.47±0.81 0.4 Direct stenting (%) 41.9 36.0 0.01

Composite of Cardiac Death, MI, Clinically Indicated TVR COMPARE II trial Multivessel treatment Primary Endpoint Composite of Cardiac Death, MI, Clinically Indicated TVR P=NS

TLF: Composite of Cardiac Death, MI, Clinically Indicated TLR COMPARE II trial Multivessel treatment Secondary Endpoint TLF: Composite of Cardiac Death, MI, Clinically Indicated TLR P=NS

(Definite & Probable; ARC Definition) COMPARE II trial Multivessel treatment Stent Thrombosis (ARC) (Definite & Probable; ARC Definition)

COMPARE II trial Multivessel treatment Conclusions Although this substudy was not powered to detect differences between the two stents, the BES with biodegradable polymer, was found as safe and effective as the EES even in this challenging patients population. This study adds valuable evidence about clinical outcomes in patients with multivessel disease treated with contemporary DES.